Updated on 2024/10/01

Information

 

写真a

 
ISOBE TAICHI
 
Organization
Faculty of Medical Sciences Center for Cohort Studies Assistant Professor
Faculty of Medical Sciences Center for Cohort Studies(Joint Appointment)
Kyushu University Hospital Hematology, Oncology & Cardiovascular medicine(Joint Appointment)
School of Medicine Department of Medicine(Joint Appointment)
Title
Assistant Professor
Profile
Basic and clinical research Clinical service

Research Areas

  • Life Science / Hematology and medical oncology

  • Life Science / Tumor diagnostics and therapeutics

  • Life Science / Tumor biology

Degree

  • Ph.D.

Research History

  • Kyushu University Graduate School of Medical Sciences Department of Oncology and Social Medicine Associate Professor

    2020.10 - 2024.3

      More details

    Country:Japan

    researchmap

  • Kyushu Univeristy Comprehensive Oncology Assistant Professor

    2024.4 - Present

      More details

    Country:Japan

    researchmap

  • 九州大学病院 血液・腫瘍・心血管内科

    2020.10 - Present

      More details

  • 2012.5-2018.9 米国Stanford大学 研究員

Research Interests・Research Keywords

  • Research theme:Characterization of immune responses in tumor mecroenvironment of patients with clonal hematopoiesis

    Keyword:Clonal hematopoiesis, Cancer, Microenvironment

    Research period: 2021.4

  • Research theme:Establishment of a new model for human colorectal cancers

    Keyword:Cancer, Chromosome abnormalities

    Research period: 2019.4

Papers

  • Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer

    Kyoko Yamaguchi, Mamoru Ito, Taichi Isobe, Sakuya Koreishi, Ryosuke Taguchi, Koki Uehara, Shohei Ueno, Takashi Imajima, Takafumi Kitazono, Kenji Tsuchihashi, Hirofumi Ohmura, Tomoyasu Yoshihiro, Kenro Tanoue, Satoshi Nishiyori, Eiji Iwama, Takahiro Maeda, Koichi Akashi, Eishi Baba

    JCO Precision Oncology   8 ( 8 )   e2300681   2024.5   eISSN:2473-4284

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:American Society of Clinical Oncology (ASCO)  

    PURPOSE

    The impact of genomic alterations on response and resistance to trastuzumab deruxtecan (T-DXd) has not been elucidated. Thus, we sought to identify factors predicting sensitivity to T-DXd in gastric or gastroesophageal junction (G/GEJ) cancer.

    METHODS

    We conducted a retrospective study using real-world clinical data and next-generation sequencing–based comprehensive genomic profiling (CGP) data from patients with advanced G/GEJ cancers, collected by the nationwide database in Japan. We analyzed the associations between genomic alterations and the patients' survivals after T-DXd treatment.

    RESULTS

    In 114 patients with human epidermal growth factor receptor-2 (HER2)–positive G/GEJ cancer treated with T-DXd, the most frequently altered genes were TP53 (82%), ERBB2 (80%), and CCNE1 (36%). Multivariate Cox regression analysis revealed CCNE1 amplification to be a significant predictor of shorter progression-free survival (PFS) after T-DXd treatment among 91 patients whose CGP samples were obtained before T-DXd (median PFS, 131 days v 189 days; hazard ratio [HR], 1.90 [95% CI, 1.02 to 3.53]; P = .044). Analyses of 1,450 G/GEJ cancers revealed significant CCNE1/ ERBB2 coamplification (41% relative to 11% CCNE1 amplification in ERBB2-nonamplified tumors; P < .0001). ERBB2-activating mutations were also detected in 3.7% of G/GEJ cancers and in 8.8% of HER2-positive G/GEJ cancers treated with T-DXd. Patients with ERBB2-mutated tumors showed shorter PFS than those without ERBB2 mutations after T-DXd treatment (mPFS, 105 v 180 days; P = .046).

    CONCLUSION

    CCNE1 amplification may confer primary resistance to T-DXd in HER2-positive G/GEJ cancer, suggesting that the cell cycle could be a potential therapeutic target in CCNE1/ERBB2 coamplified tumors. ERBB2-activating mutation may also attenuate T-DXd efficacy in HER2-positive G/GEJ cancer.

    DOI: 10.1200/po.23.00681

    Web of Science

    Scopus

    PubMed

    researchmap

  • An organism-wide atlas of hormonal signaling based on the mouse lemur single-cell transcriptome Reviewed

    Shixuan Liu, Camille Ezran, Michael F. Z. Wang, Zhengda Li, Kyle Awayan, Snigdha Agarwal, Aditi Agrawal, Ahmad Al-Moujahed, Alina Alam, Megan A. Albertelli, Paul Allegakoen, Thomas Ambrosi, Jane Antony, Steven Artandi, Fabienne Aujard, Ankit Baghel, Isaac Bakerman, Trygve. E. Bakken, Jalal Baruni, Philip Beachy, Biter Bilen, Olga Botvinnik, Scott. D. Boyd, Deviana Burhan, Kerriann M. Casey, Charles Chan, Charles. A. Chang, Stephen Chang, Ming Chen, Michael F. Clarke, Sheela Crasta, Rebecca Culver, Jessica D’Addabbo, Spyros Darmanis, Roozbeh Dehghannasiri, Song-Lin Ding, Connor V. Duffy, F. Hernán Espinoza, Jean Farup, Hannah K. Frank, Margaret Fuller, Astrid Gillich, Elias Godoy, Dita Gratzinger, Lisbeth A. Guethlein, Yan Hang, Kazuteru Hasegawa, Rebecca D. Hodge, Malachia Hoover, Franklin W. Huang, Kerwyn C. Huang, Shelly Huynh, Taichi Isobe, Carly Israel, SoRi Jang, Qiuyu Jing, Robert C. Jones, Jengmin Kang, Caitlin J. Karanewsky, Jim Karkanias, Justus Kebschull, Aaron Kershner, Lily Kim, Seung K. Kim, E. Christopher Kirk, Winston Koh, Silvana Konermann, William Kong, Corinne Lautier, Song Eun Lee, Ed S. Lein, Rebecca Lewis, Peng Li, Shengda Lin, Yin Liu, Gabriel Loeb, Wan-Jin Lu, Katherine Lucot, Liqun Luo, Ashley Maynard, Aaron McGeever, Ross Metzger, Jingsi Ming, Tom Montine, Antoine de Morree, Maurizio Morri, Karim Mrouj, Shravani Mukherjee, Ahmad Nabhan, Saba Nafees, Norma Neff, Patrick Neuhöfer, Patricia Nguyen, Jennifer Okamoto, Julia Olivieri, Youcef Ouadah, Honor Paine, Peter Parham, Jozeph L. Pendleton, Lolita Penland, Martine Perret, Angela Oliveira Pisco, Zhen Qi, Stephen R. Quake, Ute Radespiel, Thomas A. Rando, Hajanirina Noëline Ravelonjanahary, Andriamahery Razafindrakoto, Julia Salzman, Nicholas Schaum, Robert Schopler, Bronwyn Scott, Liza Shapiro, Hosu Sin, Rahul Sinha, Rene Sit, Geoff Stanley, Lubert Stryer, Varun Ramanan Subramaniam, Aditi Swarup, Michelle Tan, Weilun Tan, Alexander Tarashansky, Aris Taychameekiatchai, Kyle J. Travaglini, Andoni Urtasun, Sivakamasundari, Avin Veerakumar, Venkata N. P. Vemuri, Jean-Michel Verdier, Douglas Vollrath, Bo Wang, Bruce Wang, Gefei Wang, James Webber, Hannah Weinstein, Irving L. Weissman, Amanda L. Wiggenhorn, Cathy V. Williams, Patricia Wright, Albert Y. Wu, Angela Ruohao Wu, Timothy Ting-Hsuan Wu, Tony Wyss-Coray, BaoXiang Li, Jia Yan, Can Yang, Jinxurong Yang, Anne D. Yoder, Brian Yu, Andrea R. Yung, Yue Zhang, Jia Zhao, Zicheng Zhao, Jonathan Z. Long, Iwijn De Vlaminck, Sheng Wang, Jacques Epelbaum, Christin S. Kuo, Jérémy Terrien, Mark A. Krasnow, James E. Ferrell

    Nature Communications   15 ( 1 )   2024.3   eISSN:2041-1723

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    Abstract

    Hormones mediate long-range cell communication and play vital roles in physiology, metabolism, and health. Traditionally, endocrinologists have focused on one hormone or organ system at a time. Yet, hormone signaling by its very nature connects cells of different organs and involves crosstalk of different hormones. Here, we leverage the organism-wide single cell transcriptional atlas of a non-human primate, the mouse lemur (Microcebus murinus), to systematically map source and target cells for 84 classes of hormones. This work uncovers previously-uncharacterized sites of hormone regulation, and shows that the hormonal signaling network is densely connected, decentralized, and rich in feedback loops. Evolutionary comparisons of hormonal genes and their expression patterns show that mouse lemur better models human hormonal signaling than mouse, at both the genomic and transcriptomic levels, and reveal primate-specific rewiring of hormone-producing/target cells. This work complements the scale and resolution of classical endocrine studies and sheds light on primate hormone regulation.

    DOI: 10.1038/s41467-024-46070-9

    Scopus

    researchmap

    Other Link: https://www.nature.com/articles/s41467-024-46070-9

  • Adversarial domain translation networks for integrating large-scale atlas-level single-cell datasets Reviewed International journal

    Jia Zhao, Gefei Wang, Jingsi Ming, Zhixiang Lin, Yang Wang, Snigdha Agarwal, Aditi Agrawal, Ahmad Al-Moujahed, Alina Alam, Megan A. Albertelli, Paul Allegakoen, Thomas Ambrosi, Jane Antony, Steven Artandi, Fabienne Aujard, Kyle Awayan, Ankit Baghel, Isaac Bakerman, Trygve E. Bakken, Jalal Baruni, Philip Beachy, Biter Bilen, Olga Botvinnik, Scott D. Boyd, Deviana Burhan, Kerriann M. Casey, Charles Chan, Charles A. Chang, Stephen Chang, Ming Chen, Michael F. Clarke, Sheela Crasta, Rebecca Culver, Jessica D’Addabbo, Spyros Darmanis, Roozbeh Dehghannasiri, Song-Lin Ding, Connor V. Duffy, Jacques Epelbaum, F. Hernán Espinoza, Camille Ezran, Jean Farup, James E. Ferrell Jr, Hannah K. Frank, Margaret Fuller, Astrid Gillich, Elias Godoy, Dita Gratzinger, Lisbeth A. Guethlein, Yan Hang, Kazuteru Hasegawa, Rebecca D. Hodge, Malachia Hoover, Franklin W. Huang, Kerwyn Casey Huang, Shelly Huynh, Taichi Isobe, Carly Israel, SoRi Jang, Qiuyu Jing, Robert C. Jones, Jengmin Kang, Caitlin J. Karanewsky, Jim Karkanias, Justus Kebschull, Aaron Kershner, Lily Kim, Seung K. Kim, E. Christopher Kirk, Winston Koh, Silvana Konermann, William Kong, Mark A. Krasnow, Christin Kuo, Corinne Lautier, Song Eun Lee, Ed S. Lein, Rebecca Lewis, Peng Li, Shengda Lin, Shixuan Liu, Yin Liu, Gabriel Loeb, Jonathan Z. Long, Wan-Jin Lu, Katherine Lucot, Liqun Luo, Aaron McGeever, Ross Metzger, Jingsi Ming, Tom Montine, Antoine de Morree, Maurizio Morri, Karim Mrouj, Shravani Mukherjee, Ahmad Nabhan, Saba Nafees, Norma Neff, Patrick Neuhöfer, Patricia Nguyen, Jennifer Okamoto, Julia Olivieri, Youcef Ouadah, Honor Paine, Peter Parham, Jozeph L. Pendleton, Lolita Penland, Martine Perret, Angela Oliveira Pisco, Zhen Qi, Stephen R. Quake, Ute Radespiel, Thomas A. Rando, Hajanirina Noëline Ravelonjanahary, Andriamahery Razafindrakoto, Julia Salzman, Nicholas Schaum, Robert Schopler, Bronwyn Scott, Liza Shapiro, Hosu Sin, Rahul Sinha, Rene Sit, Geoff Stanley, Lubert Stryer, Varun Ramanan Subramaniam, Aditi Swarup, Weilun Tan, Alexander Tarashansky, Aris Taychameekiatchai, Jérémy Terrien, Kyle J. Travaglini, Andoni Urtasun, Sivakamasundari, Avin Veerakumar, Venkata Naga Pranathi Vemuri, Jean-Michel Verdier, Iwijn De Vlaminck, Douglas Vollrath, Bo Wang, Bruce Wang, Gefei Wang, Michael F. Z. Wang, Sheng Wang, James Webber, Hannah Weinstein, Irving L. Weissman, Amanda L. Wiggenhorn, Cathy V. Williams, Patricia Wright, Albert Y. Wu, Angela Ruohao Wu, Tony Wyss-Coray, Bao Xiang, Jia Yan, Can Yang, Jinxurong Yang, Anne D. Yoder, Brian Yu, Andrea R. Yung, Yue Zhang, Jia Zhao, Zicheng Zhao, Angela Ruohao Wu, Can Yang

    Nature Computational Science   2 ( 5 )   317 - 330   2022.5   eISSN:2662-8457

     More details

    Language:Others   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    The rapid emergence of large-scale atlas-level single-cell RNA-seq datasets presents remarkable opportunities for broad and deep biological investigations through integrative analyses. However, harmonizing such datasets requires integration approaches to be not only computationally scalable, but also capable of preserving a wide range of fine-grained cell populations. We have created Portal, a unified framework of adversarial domain translation to learn harmonized representations of datasets. When compared to other state-of-the-art methods, Portal achieves better performance for preserving biological variation during integration, while achieving the integration of millions of cells, in minutes, with low memory consumption. We show that Portal is widely applicable to integrating datasets across different samples, platforms and data types. We also apply Portal to the integration of cross-species datasets with limited shared information among them, elucidating biological insights into the similarities and divergences in the spermatogenesis process among mouse, macaque and human.

    DOI: 10.1038/s43588-022-00251-y

    Web of Science

    Scopus

    researchmap

    Other Link: https://www.nature.com/articles/s43588-022-00251-y

  • Molecular hallmarks of heterochronic parabiosis at single-cell resolution Reviewed International journal

    Róbert Pálovics, Andreas Keller, Nicholas Schaum, Weilun Tan, Tobias Fehlmann, Michael Borja, Fabian Kern, Liana Bonanno, Kruti Calcuttawala, James Webber, Aaron McGeever, Nicole Almanzar, Jane Antony, Ankit S. Baghel, Isaac Bakerman, Ishita Bansal, Ben A. Barres, Philip A. Beachy, Daniela Berdnik, Biter Bilen, Douglas Brownfield, Corey Cain, Charles K. F. Chan, Michelle B. Chen, Michael F. Clarke, Stephanie D. Conley, Aaron Demers, Kubilay Demir, Antoine de Morree, Tessa Divita, Haley du Bois, Hamid Ebadi, F. Hernán Espinoza, Matt Fish, Qiang Gan, Benson M. George, Astrid Gillich, Rafael Gòmez-Sjöberg, Foad Green, Geraldine Genetiano, Xueying Gu, Gunsagar S. Gulati, Oliver Hahn, Michael Seamus Haney, Yan Hang, Lincoln Harris, Mu He, Shayan Hosseinzadeh, Albin Huang, Kerwyn Casey Huang, Tal Iram, Taichi Isobe, Feather Ives, Robert C. Jones, Kevin S. Kao, Guruswamy Karnam, Aaron M. Kershner, Nathalie Khoury, Seung K. Kim, Bernhard M. Kiss, William Kong, Mark A. Krasnow, Maya E. Kumar, Christin S. Kuo, Jonathan Lam, Davis P. Lee, Song E. Lee, Benoit Lehallier, Olivia Leventhal, Guang Li, Qingyun Li, Ling Liu, Annie Lo, Wan-Jin Lu, Maria F. Lugo-Fagundo, Anoop Manjunath, Andrew P. May, Ashley Maynard, Marina McKay, M. Windy McNerney, Bryan Merrill, Ross J. Metzger, Marco Mignardi, Dullei Min, Ahmad N. Nabhan, Katharine M. Ng, Patricia K. Nguyen, Joseph Noh, Roel Nusse, Rasika Patkar, Weng Chuan Peng, Lolita Penland, Katherine Pollard, Robert Puccinelli, Zhen Qi, Thomas A. Rando, Eric J. Rulifson, Joe M. Segal, Shaheen S. Sikandar, Rahul Sinha, Rene V. Sit, Justin Sonnenburg, Daniel Staehli, Krzysztof Szade, Michelle Tan, Cristina Tato, Krissie Tellez, Laughing Bear Torrez Dulgeroff, Kyle J. Travaglini, Carolina Tropini, Margaret Tsui, Lucas Waldburger, Bruce M. Wang, Linda J. van Weele, Kenneth Weinberg, Irving L. Weissman, Michael N. Wosczyna, Sean M. Wu, Jinyi Xiang, Soso Xue, Kevin A. Yamauchi, Andrew C. Yang, Lakshmi P. Yerra, Justin Youngyunpipatkul, Brian Yu, Fabio Zanini, Macy E. Zardeneta, Alexander Zee, Chunyu Zhao, Fan Zhang, Hui Zhang, Martin Jinye Zhang, Lu Zhou, James Zou, Jian Luo, Angela Oliveira Pisco, Jim Karkanias, Norma F. Neff, Spyros Darmanis, Stephen R. Quake, Tony Wyss-Coray

    Nature   603 ( 7900 )   309 - 314   2022.3   ISSN:0028-0836 eISSN:1476-4687

     More details

    Language:Others   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    The ability to slow or reverse biological ageing would have major implications for mitigating disease risk and maintaining vitality1. Although an increasing number of interventions show promise for rejuvenation2, their effectiveness on disparate cell types across the body and the molecular pathways susceptible to rejuvenation remain largely unexplored. Here we performed single-cell RNA sequencing on 20 organs to reveal cell-type-specific responses to young and aged blood in heterochronic parabiosis. Adipose mesenchymal stromal cells, haematopoietic stem cells and hepatocytes are among those cell types that are especially responsive. On the pathway level, young blood invokes new gene sets in addition to reversing established ageing patterns, with the global rescue of genes encoding electron transport chain subunits pinpointing a prominent role of mitochondrial function in parabiosis-mediated rejuvenation. We observed an almost universal loss of gene expression with age that is largely mimicked by parabiosis: aged blood reduces global gene expression, and young blood restores it in select cell types. Together, these data lay the groundwork for a systemic understanding of the interplay between blood-borne factors and cellular integrity.

    DOI: 10.1038/s41586-022-04461-2

    Scopus

    PubMed

    researchmap

    Other Link: https://www.nature.com/articles/s41586-022-04461-2

  • Ageing hallmarks exhibit organ-specific temporal signatures Reviewed

    Nature   583 ( 7817 )   596 - 602   2020.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41586-020-2499-y

  • A single-cell transcriptomic atlas characterizes ageing tissues in the mouse Reviewed

    Tabula Muris Consortium

    Nature   583 ( 7817 )   590 - 595   2020.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41586-020-2496-1

  • miR-221 Targets QKI to Enhance the Tumorigenic Capacity of Human Colorectal Cancer Stem Cells. Reviewed International journal

    Junko Mukohyama, Taichi Isobe, Qingjiang Hu, Takanori Hayashi, Takashi Watanabe, Masao Maeda, Hisano Yanagi, Xin Qian, Kimihiro Yamashita, Hironobu Minami, Koshi Mimori, Debashis Sahoo, Yoshihiro Kakeji, Akira Suzuki, Piero Dalerba, Yohei Shimono

    Cancer research   79 ( 20 )   5151 - 5158   2019.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1158/0008-5472.CAN-18-3544

  • Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Reviewed

    Tabula Muris Consortium

    Nature   562   367 - 372   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris.

    DOI: 10.1038/s41586-018-0590-4

  • E‑cadherin regulates proliferation of colorectal cancer stem cells through NANOG. Reviewed International journal

    40 ( 2 )   693 - 703   2018.8

     More details

    Language:English  

    DOI: 10.3892/or.2018.6464

  • miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway Reviewed

    Taichi Isobe, Shigeo Hisamori, Daniel J. Hogan, Maider Zabala, David G. Hendrickson, Piero Dalerba, Shang Cai, Ferenc Scheeren, Angera H. Kuo, Shaheen S. Sikandar, Jessica S. Lam, Dalong Qian, Frederick M. Dirbas, George Somlo, Kaiqin Lao, Patrick O. Brown, Michael F. Clarke, Yohei Shimono

    ELIFE   3   2014.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.7554/eLife.01977

  • Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan Reviewed

    Taichi Isobe, Keita Uchino, Chinatsu Makiyama, Hiroshi Ariyama, Shuji Arita, Shingo Tamura, Masato Komoda, Hitoshi Kusaba, Tsuyoshi Shirakawa, Taito Esaki, Kenji Mitsugi, Shigeo Takaishi, Koichi Akashi, Eishi Baba

    ANTICANCER RESEARCH   34 ( 4 )   2035 - 2040   2014.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Human STEAP3 maintains tumor growth under hypoferric condition Reviewed

    Taichi Isobe, Eishi Baba, Shuji Arita, Masato Komoda, Shingo Tamura, Tsuyoshi Shirakawa, Hiroshi Ariyama, Shigeo Takaishi, Hitoshi Kusaba, Takashi Ueki, Koichi Akashi

    EXPERIMENTAL CELL RESEARCH   317 ( 18 )   2582 - 2591   2011.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.yexcr.2011.07.022

  • Effective monotherapy with amrubicin for a refractory extrapulmonary small-cell carcinoma of the liver. Reviewed

    Isobe T, Yanai S, Kusaba H, Yada S, Kuroda Y, Tamiya S, Matsumoto T, Baba E, Harada M

    Case reports in medicine   2009   538081   2009.6

     More details

    Language:English  

    Effective monotherapy with amrubicin for a refractory extrapulmonary small-cell carcinoma of the liver.

    DOI: 10.1155/2009/538081

  • Autoimmune thrombocytopenia with clonal expansion of CD8-positive T cells after autologous peripheral blood stem cell transplantation for diffuse large B-cell lymphoma Reviewed

    T Isobe, TE Tanimoto, G Nakaji, T Miyamoto, S Yamasaki, K Takase, A Numata, T Fukuda, K Nagafuji, S Inaba, M Harada

    BONE MARROW TRANSPLANTATION   35 ( 3 )   315 - 316   2005.2

     More details

    Language:English  

    DOI: 10.1038/sj.bmt.1704750

  • Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan Reviewed

    Kenji Tsuchihashi, Mamoru Ito, Shuji Arita, Hitoshi Kusaba, Wataru Kusano, Takashi Matsumura, Takafumi Kitazono, Shohei Ueno, Ryosuke Taguchi, Tomoyasu Yoshihiro, Yasuhiro Doi, Kohei Arimizu, Hirofumi Ohmura, Tatsuhiro Kajitani, Kenta Nio, Michitaka Nakano, Kotoe Oshima, Shingo Tamura, Tsuyoshi Shirakawa, Hozumi Shimokawa, Keita Uchino, Fumiyasu Hanamura, Yuta Okumura, Masato Komoda, Taichi Isobe, Hiroshi Ariyama, Taito Esaki, Kazuki Hashimoto, Noritaka Komune, Mioko Matsuo, Keiji Matsumoto, Kaori Asai, Tadamasa Yoshitake, Hidetaka Yamamoto, Yoshinao Oda, Koichi Akashi, Eishi Baba

    BMC Cancer   23 ( 1 )   1046   2023.10   eISSN:1471-2407

     More details

    Language:Others   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    Abstract

    Background

    Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy.

    Methods

    We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy.

    Results

    Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows: median age: 38 years (range 25 – 63 years), histology (alveolar/spindle): 10/1, and risk group (intermediate/high): 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95%CI: 6.0 – 25.8 months): 17.1 months (95%CI: 6.0 – not reached (NR)) for patients with stage I-III and 8.5 months (95%CI: 5.2 – 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5% and 11.3% for all patients. Median OS in all patients was 40.8 months (95%CI: 12.1 months–NR): 40.8 months (95%CI: 12.1 – NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5% for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions.

    Conclusion

    The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions.

    DOI: 10.1186/s12885-023-11528-4

    Web of Science

    Scopus

    PubMed

    researchmap

    Other Link: https://link.springer.com/article/10.1186/s12885-023-11528-4/fulltext.html

  • Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions. Reviewed International journal

    Koki Uehara, Kenro Tanoue, Kyoko Yamaguchi, Hirofumi Ohmura, Mamoru Ito, Yuzo Matsushita, Kenji Tsuchihashi, Shingo Tamura, Hozumi Shimokawa, Taichi Isobe, Yoshihiro Shibata, Hiroshi Ariyama, Risa Tanaka, Hitoshi Kusaba, Hidetaka Yamamoto, Yoshinao Oda, Koichi Akashi, Eishi Baba

    Cancer immunology, immunotherapy : CII   72 ( 11 )   3543 - 3558   2023.8   ISSN:0340-7004 eISSN:1432-0851

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Combined immune checkpoint blockade (ICB) is effective therapy for renal cell carcinoma (RCC). However, the dynamic changes in circulating B cells induced by combined ICB have not been clarified. The present study prospectively examined 22 patients scheduled to receive ICB for unresectable or metastatic RCC between March 2018 and August 2021. Eleven patients received combined therapy with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab), and the other 11 patients received nivolumab monotherapy. Comprehensive phenotypes of circulating immune cells obtained prior to and after ICB therapy were analyzed by flow cytometry. Although the proportion of naïve B cells among total B cells was significantly decreased, that of switched memory B cells was significantly increased after combined therapy. In responders, the proportion of B cells among peripheral blood mononuclear cells was significantly higher prior to ICB therapy, and the proportion of switched memory B cells among total B cells tended to increase after ICB therapy. Of note, the proportion of plasmablasts among total B cells was significantly increased after ICB therapy in patients who developed severe immune-related adverse events (irAEs), and the proportion of B cells among peripheral blood decreased significantly. Furthermore, in four of five patients who developed immune-related hypophysitis following combined therapy, anti-pituitary antibody was detected in the serum. These results suggested that immune-related hypophysitis was closely related to the increase in circulating plasmablasts. Collectively, this study suggests that combined ICB promotes the differentiation of B cell populations, which is associated with efficient tumor suppression and development of irAEs.

    DOI: 10.1007/s00262-023-03505-4

    Web of Science

    Scopus

    PubMed

    researchmap

  • RHAMM marks proliferative subpopulation of human colorectal cancer stem cells. Reviewed

    Michitaka Nakano, Taguchi R, Kikushige Y, Taichi Isobe, Kohta Miyawaki, Mizuno S, Tsuruta N, Hanamura F, Yamaguchi K, Yamauchi T, Hiroshi Ariyama, Kusaba H, Nakamura M, Maeda T, Kuo CJ, Eishi Baba, Akashi K

    Cancer science   114 ( 7 )   2895 - 2906   2023.3   ISSN:1347-9032 eISSN:1349-7006

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    The cancer stem cell (CSC) theory features typically rare self-renewing subpopulation that reconstitute the heterogeneous tumor. Identification of molecules which characterize the feature of CSCs is a key imperative for further understanding of tumor heterogeneity and for the development of novel therapeutic strategies. However, the use of conventional markers of CSCs is still insufficient for the isolation of bona fide CSCs. We investigated organoids which are miniature forms of tumor tissues with reconstructing cellular diversity to identify specific marker to characterize CSCs in heterogeneous tumors. Here, we report that receptor for hyaluronan-mediated motility (RHAMM) expresses in a subpopulation of CD44+ conventional human colorectal CSC fraction. Single-cell transcriptomics of organoids highlighted RHAMM positive proliferative cells that revealed distinct characteristics among the various cell types. Prospectively isolated RHAMM+ CD44+ cells from the human colorectal cancer tissues showed highly proliferative character with self-renewal ability in comparison with the other cancer cells. Furthermore, inhibition of RHAMM strongly suppressed organoids formation in vitro and inhibited the tumor growth in vivo. Our findings suggest that RHAMM is a potential therapeutic target because it is a specific marker of the proliferative subpopulation within the conventional CSC fraction.

    DOI: 10.1111/cas.15795

    Web of Science

    Scopus

    PubMed

    researchmap

  • IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism. Reviewed International journal

    Hitoshi Kusaba, Shohei Moriyama, Michinari Hieda, Mamoru Ito, Hirofumi Ohmura, Taichi Isobe, Kenji Tsuchihashi, Mitsuhiro Fukata, Hiroshi Ariyama, Eishi Baba

    Japanese journal of clinical oncology   52 ( 10 )   1183 - 1190   2022.10   ISSN:0368-2811 eISSN:1465-3621

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The incidence of venous thromboembolism has been reported as 20% in cancer patients. Anticoagulation therapy is the standard treatment for venous thromboembolism. On the other hand, bleeding should be carefully managed, because advanced cancer, particularly gastrointestinal cancer, carries a high risk of bleeding. However, the optimal management for cancer-associated thromboembolism remains to be clarified. METHODS: We retrospectively examined patients with advanced gastrointestinal cancer, including gastric cancer and colorectal cancer, who were treated with chemotherapy between 2014 and 2018 for the incidence and characteristics of venous thromboembolism and bleeding. RESULTS: In total, 194 patients (120 men, 74 women) were enrolled in this study. The underlying pathology was gastric cancer in 74 cases and colorectal cancer in 120 cases. Of the 194 patients, 40 patients (20.6%) were diagnosed with venous thromboembolism and 10 patients (5.2%) were diagnosed with concomitant pulmonary thromboembolism. Conversely, bleeding was observed in 29 patients (15%). The location of bleeding was the primary tumor in 17 cases, metastatic tumor in 9 and hemorrhagic gastric ulcer in 3. Within the venous thromboembolism group (n = 40), bleeding was observed in 10 patients (25%). Multivariate analysis showed that International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) bleeding score ≥7 correlated significantly with major bleeding (P = 0.01). In patients with a low risk of bleeding, major bleeding was observed in only three patients. CONCLUSIONS: IMPROVE bleeding score may predict the risk for bleeding in gastrointestinal cancer patients with venous thromboembolism. Selecting patients with a low risk of bleeding using with IMPROVE bleeding score is expected to contribute to the safer management of anticoagulation therapy for cancer-associated thromboembolism.

    DOI: 10.1093/jjco/hyac103

    Web of Science

    Scopus

    PubMed

    researchmap

  • Inhibition of insulin-like growth factor-1 receptor enhances eribulin-induced DNA damage in colorectal cancer. Reviewed International journal

    Tomoyasu Yoshihiro, Hiroshi Ariyama, Kyoko Yamaguchi, Takashi Imajima, Satoru Yamaga, Kenji Tsuchihashi, Taichi Isobe, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Cancer science   113 ( 12 )   4207 - 4218   2022.9   ISSN:1347-9032 eISSN:1349-7006

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Microtubule targeting agents (MTAs) such as taxanes are broadly used for the treatment of patients with cancer. Although MTAs are not effective for treatment of colorectal cancer (CRC), preclinical studies suggest that a subset of patients with CRC, especially those with cancers harboring the BRAF mutation, could benefit from such agents. However, two MTAs, eribulin (Eri) and vinorelbine, have shown limited clinical efficacy. Here, we report that insulin-like growth factor 1 receptor (IGF-1R) signaling is involved in Eri resistance. Using CRC cell lines, we showed that Eri induces activation and subsequent translocation of IGF-1R to the nucleus. When the activation and/or nuclear translocation of IGF-1R was inhibited, Eri induced DNA damage and enhanced G2 /M arrest. In a xenograft model using the Eri-resistant SW480 cell line, the combination of Eri and the IGF-1R inhibitor linsitinib suppressed tumor growth more efficiently than either single agent. Thus, our results indicated that combination dosing with Eri and an IGF-1R inhibitor could overcome Eri resistance and offer a therapeutic opportunity in CRC.

    DOI: 10.1111/cas.15558

    Web of Science

    Scopus

    PubMed

    researchmap

  • Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model. Reviewed

    Kyoko Yamaguchi, Tomoyasu Yoshihiro, Hiroshi Ariyama, Mamoru Ito, Michitaka Nakano, Yuichiro Semba, Jumpei Nogami, Kenji Tsuchihashi, Takuji Yamauchi, Shohei Ueno, Taichi Isobe, Koji Shindo, Taiki Moriyama, Kenoki Ohuchida, Masafumi Nakamura, Yoshihiro Nagao, Tetsuo Ikeda, Makoto Hashizume, Hiroyuki Konomi, Takehiro Torisu, Takanari Kitazono, Tomohiro Kanayama, Hiroyuki Tomita, Yoshinao Oda, Hitoshi Kusaba, Takahiro Maeda, Koichi Akashi, Eishi Baba

    Gastric cancer   25 ( 5 )   862 - 878   2022.6   ISSN:1436-3291 eISSN:1436-3305

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Loss of E-cadherin expression is frequently observed in signet ring carcinoma (SRCC). People with germline mutations in CDH1, which encodes E-cadherin, develop diffuse gastric cancer at a higher rate. Loss of E-cadherin expression is thus assumed to trigger oncogenic development. METHODS: To investigate novel therapeutic targets for gastric SRCC, we engineered an E-cadherin-deficient SRCC model in vitro using a human gastric organoid (hGO) with CDH1 knockout (KO). RESULTS: CDH1 KO hGO cells demonstrated distinctive morphological changes similar to SRCC and high cell motility. RNA-sequencing revealed up-regulation of matrix metalloproteinase (MMP) genes in CDH1 KO hGO cells compared to wild type. MMP inhibitors suppressed cell motility of CDH1 KO hGO cells and SRCC cell lines in vitro. Immunofluorescent analysis with 95 clinical gastric cancer tissues revealed that MMP-3 was specifically abundant in E-cadherin-aberrant SRCC. In addition, CXCR4 molecules translocated onto the cell membrane after CDH1 KO. Addition of CXCL12, a ligand of CXCR4, to the culture medium prolonged cell survival of CDH1 KO hGO cells and was abolished by the inhibitor, AMD3100. In clinical SRCC samples, CXCL12-secreting fibroblasts showed marked infiltration into the cancer area. CONCLUSIONS: E-cadherin deficient SRCCs might gain cell motility through upregulation of MMPs. CXCL12-positive cancer-associated fibroblasts could serve to maintain cancer-cell survival as a niche. MMPs and the CXCL12/CXCR4 axis represent promising candidates as novel therapeutic targets for E-cadherin-deficient SRCC.

    DOI: 10.1007/s10120-022-01307-8

    Web of Science

    Scopus

    PubMed

    researchmap

  • Upregulation of BMI1-suppressor miRNAs (miR-200c, miR-203) during terminal differentiation of colon epithelial cells. Reviewed International coauthorship

    Shigeo Hisamori, Junko Mukohyama, Sanjay Koul, Takanori Hayashi, Michael Evan Rothenberg, Masao Maeda, Taichi Isobe, Luis Enrique Valencia Salazar, Xin Qian, Darius Michael Johnston, Dalong Qian, Kaiqin Lao, Naoya Asai, Yoshihiro Kakeji, Vincenzo Alessandro Gennarino, Debashis Sahoo, Piero Dalerba, Yohei Shimono

    Journal of gastroenterology   57 ( 6 )   407 - 422   2022.3   ISSN:0944-1174 eISSN:1435-5922

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media {LLC}  

    BACKGROUND: MicroRNAs (miRNAs) are key regulators of stem cell functions, including self-renewal and differentiation. In this study, we aimed to identify miRNAs that are upregulated during terminal differentiation in the human colon epithelium, and elucidate their role in the mechanistic control of stem cell properties. METHODS: "Bottom-of-the-crypt" (EPCAM+/CD44+/CD66alow) and "top-of-the-crypt" (EPCAM+/CD44neg/CD66ahigh) epithelial cells from 8 primary colon specimens (6 human, 2 murine) were purified by flow cytometry and analyzed for differential expression of 335 miRNAs. The miRNAs displaying the highest upregulation in "top-of-the-crypt" (terminally differentiated) epithelial cells were tested for positive correlation and association with survival outcomes in a colon cancer RNA-seq database (n = 439 patients). The two miRNAs with the strongest "top-of-the-crypt" expression profile were evaluated for capacity to downregulate self-renewal effectors and inhibit in vitro proliferation of colon cancer cells, in vitro organoid formation by normal colon epithelial cells and in vivo tumorigenicity by patient-derived xenografts (PDX). RESULTS: Six miRNAs (miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-345) were upregulated in "top-of-the-crypt" cells and positively correlated in expression among colon carcinomas. Overexpression of the three miRNAs with the highest inter-correlation coefficients (miR-200a, miR-200b, miR-200c) associated with improved survival. The top two over-expressed miRNAs (miR-200c, miR-203) cooperated synergistically in suppressing expression of BMI1, a key regulator of self-renewal in stem cell populations, and in inhibiting proliferation, organoid-formation and tumorigenicity of colon epithelial cells. CONCLUSION: In the colon epithelium, terminal differentiation associates with the coordinated upregulation of miR-200c and miR-203, which cooperate to suppress BMI1 and disable the expansion capacity of epithelial cells.

    DOI: 10.1007/s00535-022-01865-9

    Scopus

    PubMed

    CiNii Research

    researchmap

    Other Link: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21K07152/

  • Macrophages are primed to transdifferentiate into fibroblasts in malignant ascites and pleural effusions. Reviewed International journal

    Mamoru Ito, Michitaka Nakano, Hiroshi Ariyama, Kyoko Yamaguchi, Risa Tanaka, Yuichiro Semba, Takeshi Sugio, Kohta Miyawaki, Yoshikane Kikushige, Shinichi Mizuno, Taichi Isobe, Kenro Tanoue, Ryosuke Taguchi, Shohei Ueno, Takahito Kawano, Masaharu Murata, Eishi Baba, Koichi Akashi

    Cancer letters   532   215597 - 215597   2022.2   ISSN:0304-3835 eISSN:1872-7980

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cancer-associated fibroblasts (CAFs) play an important role in cancer progression. However, the origin of CAFs remains unclear. This study shows that macrophages in malignant ascites and pleural effusions (cavity fluid-associated macrophages: CAMs) transdifferentiate into fibroblast-like cells. CAMs obtained from gastrointestinal cancer patients were sorted by flow cytometry and cultured in vitro. CD45+CD14+ CAMs transdifferentiated into CD45-CD90+ fibroblast-like cells that exhibited spindle shapes. Then, cDNA microarray analysis showed that the CD45-CD90+ fibroblast-like cells (macrophage-derived CAFs: MDCAFs) had a fibroblast-specific gene expression signature and produced growth factors for epithelial cell proliferation. Human colon cancer cells transplanted into immunodeficient mice with MDCAFs formed larger tumors than cancer cells alone. Gene ontology analyses showed the involvement of TGFβ signaling and cell-matrix adhesion in MDCAFs, and transdifferentiation of CAMs into MDCAFs was canceled by inhibiting TGFβ and cell adhesion. Furthermore, the acquired genetic alterations in hematopoietic stem cells (HSCs) were shared in CAMs and MDCAFs. Taken together, CAMs could be a source of CAFs and might originate from HSCs. We propose the transdifferentiation process of CAMs into MDCAFs as a new therapeutic target for fibrosis associated with gastrointestinal cancer.

    DOI: 10.1016/j.canlet.2022.215597

    Web of Science

    Scopus

    PubMed

    researchmap

  • PD-L1 expression is regulated by RNA N6-methyladenosine demethylase FTO in colon cancer cells

    Tsuchihashi, K; Tsuruta, N; Ohmura, H; Yamaguchi, K; Ito, M; Tanoue, K; Isobe, T; Ariyama, H; Kusaba, H; Akashi, K; Baba, E

    CANCER SCIENCE   113   1331 - 1331   2022.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients? International journal

    Eijiro Shimada, Makoto Endo, Yoshihiro Matsumoto, Kenji Tsuchihashi, Mamoru Ito, Hitoshi Kusaba, Akira Nabeshima, Tomoya Nawata, Akira Maekawa, Tomoya Matsunobu, Nokitaka Setsu, Toshifumi Fujiwara, Keiichiro Iida, Makoto Nakagawa, Takeshi Hirose, Masaya Kanahori, Ryunosuke Oyama, Taichi Isobe, Hiroshi Ariyama, Kenichi Kohashi, Hidetaka Yamamoto, Yoshinao Oda, Yukihide Iwamoto, Koichi Akashi, Eishi Baba, Yasuharu Nakashima

    Journal of clinical medicine   10 ( 21 )   2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/jcm10214972

  • Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy

    Kyoko Yamaguchi, Kenji Tsuchihashi, Kunihiro Tsuji, Yosuke Kito, Kenro Tanoue, Hirofumi Ohmura, Mamoru Ito, Taichi Isobe, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Medicine   100 ( 19 )   e25773 - e25773   2021.5

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/md.0000000000025773

  • Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab Reviewed

    Tanoue, Kenro, Tamura, Shingo, Kusaba, Hitoshi, Shinohara, Yudai, Ito, Mamoru, Tsuchihashi, Kenji, Shirakawa, Tsuyoshi, Otsuka, Taiga, Ohmura, Hirofumi, Isobe, Taichi, Ariyama, Hiroshi, Koreishi, Sakuya, Matsushita, Yuzo, Shimokawa, Hozumi, Tanaka, Risa, Mitsugi, Kenji, Akashi, Koichi, Baba, Eishi

    Scientific Reports   2021.2

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/S41598-021-82448-1

  • Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin Reviewed

    Kenji Tsuchihashi, Hitoshi Kusaba, Tomoyasu Yoshihiro, Toshifumi Fujiwara, Nokitaka Setsu, Makoto Endo, Yoshihiro Matsumoto, Takashi Imajima, Yudai Shinohara, Mamoru Ito, Satoru Yamaga, Kenro Tanoue, Kohei Arimizu, Hirofumi Ohmura, Fumiyasu Hanamura, Kyoko Yamaguchi, Taichi Isobe, Hiroshi Ariyama, Yasuharu Nakashima, Koichi Akashi, Eishi Baba

    Scientific Reports   10 ( 1 )   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41598-020-77898-y

  • Methylation of drug resistance‐related genes in chemotherapy‐sensitive Epstein–Barr virus‐associated gastric cancer Reviewed

    10 ( 1 )   147 - 157   2020.1

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/2211-5463.12765

  • Organoid Culture of Human Cancer Stem Cells. Reviewed

    Shimono Y, Mukohyama J, Isobe T, Johnston DM, Dalerba P, Suzuki A

    Methods in molecular biology (Clifton, N.J.)   2016.9

     More details

    Language:Others  

    Organoid Culture of Human Cancer Stem Cells.

    DOI: 10.1007/7651_2016_13

  • Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy Reviewed

    Kenta Nio, Shuji Arita, Taichi Isobe, Hitoshi Kusaba, Kenichi Kohashi, Tatsuhiro Kajitani, Shingo Tamura, Gen Hirano, Kenji Mitsugi, Akitaka Makiyama, Taito Esaki, Hiroshi Ariyama, Yoshinao Oda, Koichi Akashi, Eishi Baba

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   75 ( 4 )   829 - 835   2015.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00280-015-2706-y

  • Systemic chemotherapy for metastatic non-mucinous appendiceal adenocarcinoma: a case report and literature review Reviewed

    Kenji Tsuchihashi, Kotoe Takayoshi, Keita Uchino, Tsuyoshi Shirakawa, Hozumi Kumagai, Shingo Tamura, Masato Komoda, Taichi Isobe, Shigeo Takaishi, Hitoshi Kusaba, Shinichi Aishima, Koichi Akashi, Eishi Baba

    International Cancer Conference Journal   2 ( 1 )   36 - 40   2013.1

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s13691-012-0060-z

  • Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells Reviewed

    Keita Uchino, Gen Hirano, Minako Hirahashi, Taichi Isobe, Tsuyoshi Shirakawa, Hitoshi Kusaba, Eishi Baba, Masazumi Tsuneyoshi, Koichi Akashi

    EXPERIMENTAL CELL RESEARCH   318 ( 15 )   1799 - 1807   2012.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.yexcr.2012.04.011

  • Improvement of quality of life and survival using self-expandable metal stent placement for severe malignant stenosis of the gastric body: A case report Reviewed

    Hozumi Kumagai, Kenta Nio, Tsuyoshi Shirakawa, Keita Uchino, Hitoshi Kusaba, Taichi Isobe, Masato Komoda, Shingo Tamura, Ryo Maeyama, Eishi Nagai, Koichi Akashi, Eishi Baba

    Journal of Medical Case Reports   6 ( 1 )   315   2012.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/1752-1947-6-315

  • Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma Reviewed

    Yoshihiro Shibata, Eishi Baba, Hiroshi Ariyama, Shuji Arita, Taichi Isobe, Hitoshi Kusaba, Kenji Mitsugi, Shuji Nakano, Koichi Akashi

    ONCOLOGY LETTERS   1 ( 3 )   423 - 426   2010.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3892/ol_00000074

  • Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines Reviewed

    Akitaka Makiyama, Baoli Qin, Keita Uchino, Yoshihiro Shibata, Shuji Arita, Taichi Isobe, Gen Hirano, Hitoshi Kusaba, Eishi Baba, Koichi Akashi, Shuji Nakano

    ANTI-CANCER DRUGS   20 ( 2 )   123 - 130   2009.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/CAD.0b013e3283218080

  • B cell activation regulates exosomal HLA production Reviewed

    Shuji Arita, Eishi Baba, Yoshihiro Shibata, Hiroaki Niiro, Shinji Shimoda, Taichi Isobe, Hitoshi Kusaba, Shuji Nakano, Mine Harada

    EUROPEAN JOURNAL OF IMMUNOLOGY   38 ( 5 )   1423 - 1434   2008.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/eji.200737694

▼display all

Books

  • 新臨床腫瘍学(改訂第7版)

    日本臨床腫瘍学会( Role: Editコアメンバー)

    南江堂  2024.4    ISBN:978-4-524-20426-7

     More details

    Language:Japanese   Book type:Textbook, survey, introduction

Presentations

▼display all

MISC

▼display all

Professional Memberships

  • The Japanese Society of Internal Medicine

  • Japanese Cancer Association

  • Japanese Society of Medical Oncology

  • American Association for Cancer Research (AACR)

  • American Society of Clinical Oncology (ASCO)

  • International Society for Stem Cell Research (ISSCR)

  • The Japanese Society of Gastroenterology

▼display all

Academic Activities

  • Scientific Reports International contribution

    2022.8 - 2032.8

     More details

    Type:Academic society, research group, etc. 

  • Screening of academic papers

    Role(s): Peer review

    2021

     More details

    Type:Peer review 

    Number of peer-reviewed articles in foreign language journals:2

Research Projects

  • User The development of novel senolytics for gastrointestinal cancers with clonal hematopoiesis

    Grant number:24K11170  2024 - 2026

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    CiNii Research

  • Characterization of immune responses in tumor microenvironment of patients with clonal hematopoiesis

    Grant number:21K07152  2021 - 2023

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    CiNii Research

  • 染色体異常を起因としたヒト大腸がんの新規疾患モデルの確立

    Grant number:19K17831  2019 - 2020

    日本学術振興会  科学研究費助成事業  若手研究

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • 新規疾患モデルを用いた染色体変異による大腸発がんメカニズムの解明

    2019 - 2020

    公益財団法人新日本先進医療研究財団 令和元年度(第5回)研究助成金

      More details

    Authorship:Principal investigator  Grant type:Contract research

  • 細胞順応による初期転移巣成立機構解析の基盤構築

    Grant number:15K14381  2015 - 2016

    科学研究費助成事業  挑戦的萌芽研究

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

Educational Activities

  • Mentoring PhD students
    Mentoring students at clinical practice

FD Participation

  • 2022.12   Role:Participation   Title:医学系学府教育FD「医学系大学院プログラムの進化と深化をめざして」

  • 2022.8   Role:Participation   Title:医学部医学科・生命科学科FD「医学教育分野別評価受審の振り返りについて」

  • 2021.12   Role:Participation   Title:医学系学府教育FD「学術論文の購読と投稿とこれから」

Other educational activity and Special note

  • 2023  Class Teacher 

  • 2022  Class Teacher 

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Internal Medicine / General Internal Medicine (including psychosomatic medicine)

    腫瘍内科

Clinician qualification

  • 総合内科専門医

    The Japanese Society of Internal Medicine(JSIM)

  • 認定内科医

    The Japanese Society of Internal Medicine(JSIM)

  • Preceptor

    The Japanese Society of Internal Medicine(JSIM)

  • Certifying physician

    日本がん治療認定医機構

Year of medical license acquisition

  • 2003

Notable Clinical Activities

  • 腫瘍内科